EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
DEAR ABBY: Eye exams can save more than your vision
DEAR ABBY: I’m an ophthalmologist, a physician who specializes in medical and surgical eye care, and I’m hoping…
Stem cell therapy helps AMD patients see again: Study
Washington DC [US], November 23 (ANI): A first-of-its-kind trial is testing adult stem cell transplants for advanced dry…